錦雞股份(300798.SZ):英智創新簽訂3.12億元AI服務器採購合同
格隆匯10月20日丨錦雞股份(300798.SZ)公佈,公司全資子公司英智創新(深圳)科技有限公司(簡稱:“英智創新”)擬在廣東省深圳市南山區等地投資建設《AI創新賦能中心項目》(以下簡稱:“AI項目”)。項目計劃分期建設具有10000P算力的智算算力網,其中一期建設規模為2000P算力,二期建設規模為8000P算力,合計共建設具備10000P算力覆蓋全國的算力網絡。
為積極推進AI項目建設,近日,公司全資子公司英智創新與北京深灣科技有限公司簽訂《AI服務器採購合同》,採購H800 80GB HGX NVLINK服務器,NF5688M7。合同含税總價人民幣3.12億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.